International Journal of Science and Research (IJSR)
ISSN: 2319-7064
SJIF (2022): 7.942

Chemotherapy-Induced Neurotoxicity

Jassim Rahiman K

Assistant Professor, Department of Kayachikitsa, Apex Institute of Ayurvedic Medicine and Hospital, Chunar-231304, Mirzapur, Uttar Pradesh
Email: *jassirhmn[at]gmail.com*

Abstract: ***Chemotherapy-induced neurotoxicity is a significant challenge in cancer treatment affecting 30 -40% of patients and manifesting as both central and peripheral nervous system complications. Common neurotoxic agents include platinum-based compounds, taxanes, vinca alkaloids, proteasome inhibitors, and immunomodulatory drugs. These agents can lead to a range of symptoms including peripheral neuropathy, cognitive dysfunction and severe neuropsychiatric effects, which can limit the dose of chemotherapy and duration compromising treatment efficacy. The mechanisms underlying chemotherapy-induced neurotoxicity involve oxidative stress, mitochondrial dysfunction, DNA damage, microtubule disruption, and inflammatory processes. Current strategies for managing neurotoxicity include dose modification, drug substitution, and the use of neuroprotective agents like calcium and magnesium infusions, glutathione, and duloxetine. However, these approaches are not always effective and research is ongoing to develop more targeted therapies. Future directions in this field include the identification of biomarkers for susceptibility to neurotoxicity, the development of less neurotoxic therapeutic agents and the integration of rehabilitation and supportive care to maintain patient quality of life. Collaborative efforts between healthcare professionals are essential to mitigating the impact of neurotoxicity on cancer treatment outcomes. This review explores the mechanisms underlying chemotherapy induced neurotoxicity, current management strategies and potential future directions in research aimed at reducing the neurotoxic burden on cancer patients.***

Keywords: Neurotoxicity, Chemotherapy, Peripheral Neuropathy, Cancer Treatment, Neuroprotective Agents

1. Introduction

Cancer chemotherapy has revolutionized the treatment of various malignancies significantly improving survival rates and quality of life for many patients. However, despite these advancements chemotherapy is often associated with a range of adverse effects among which neurotoxicity is one of the most debilitating. Neurotoxicity occurs in approximately 30-40% of patients undergoing chemotherapy depending on the type and duration of treatment with certain drugs posing a higher risk.

Common neurotoxic agents include platinum-based compounds such as cisplatin and oxaliplatin, taxanes like paclitaxel and vinca alkaloids such as vincristine. These agents can lead to a spectrum of neurological complications affecting both the central and peripheral nervous systems. For instance, cisplatin-induced peripheral neuropathy can occur in up to 70% of patients presenting as numbness, tingling or pain in the extremities which can persist long after the cessation of treatment.

These toxicities not only impact the quality of life but can also limit the dose and duration of chemotherapy thereby compromising treatment efficacy. The neurotoxicity can manifest as cognitive dysfunction, sensory neuropathy or even severe neuropsychiatric symptoms complicating the therapeutic regimen and patient compliance.

Given the significant impact of neurotoxicity on cancer treatment outcomes there is a growing need for effective strategies to prevent and manage these complications. Current approaches include dose adjustment, the use of neuroprotective agents and symptom management through pharmacological and non-pharmacological interventions. However, these strategies are not always effective and research is ongoing to better understand the underlying mechanisms of chemotherapy-induced neurotoxicity and to develop more targeted therapies.

This review aims to provide a comprehensive overview of the neurotoxic agents commonly used in cancer chemotherapy focusing on the mechanisms of neurotoxicity, clinical manifestations, and current strategies for prevention and management. By understanding these factors healthcare professionals can better anticipate, identify and mitigate neurotoxicity in cancer patients.

2. Methods

A systematic literature search was conducted using databases such as PubMed, Scopus, and Web of Science to identify relevant studies published between 2000 and 2023. Search terms included "cancer chemotherapy," "neurotoxicity," "neurotoxic agents," "neuropathy," "central nervous system toxicity," and "peripheral nervous system toxicity." Inclusion criteria were studies focusing on neurotoxic effects of chemotherapeutic agents in human subjects. Studies solely on animal models or lacking substantial clinical data were excluded. Data were extracted and synthesized to provide an up-to-date analysis of the neurotoxic effects of chemotherapy agents.

3. Results

3.1 Neurotoxic Chemotherapeutic Agents

Chemotherapeutic agents associated with neurotoxicity can be broadly classified based on the type of neurological damage they induce central nervous system (CNS) toxicity and peripheral nervous system (PNS) toxicity. The major classes of neurotoxic agents include platinum-based compounds, taxanes, vinca alkaloids, proteasome inhibitors and immunomodulatory drugs.

a) Platinum-Based Compounds

Platinum-based chemotherapeutic agents including cisplatin, carboplatin, and oxaliplatin are among the most widely used agents that induce neurotoxicity. Cisplatin is particularly notorious for causing peripheral neuropathy characterized by sensory deficits, pain and motor weakness. The neurotoxicity is dose-dependent and often irreversible leading to significant long-term morbidity [1].

The mechanism of cisplatin-induced neurotoxicity involves the formation of platinum-DNA adducts, which disrupt neuronal DNA repair and induce apoptosis. Additionally oxidative stress and mitochondrial dysfunction have been implicated in neuronal damage [2]. Oxaliplatin, another platinum compound is associated with acute neurotoxicity, often presenting as cold-induced dysesthesias, a condition unique to this agent [3].

b) Taxanes

Taxanes including paclitaxel and docetaxel are microtubule-stabilizing agents used in the treatment of breast, ovarian and lung cancers. Paclitaxel-induced peripheral neuropathy (PIPN) is a common and dose-limiting side effect. Symptoms include burning pain, numbness, and tingling in a "stocking-glove" distribution. The exact pathophysiology of PIPN is not fully understood but it is believed to involve microtubule disruption in peripheral nerves leading to axonal degeneration and impaired axonal transport [4].

c) Vinca Alkaloids

Vinca alkaloids such as vincristine, vinblastine and vinorelbine are antimitotic agents that inhibit microtubule formation. Vincristine is particularly associated with neurotoxicity causing both peripheral neuropathy and CNS effects. Symptoms of vincristine-induced neuropathy include muscle weakness, loss of deep tendon reflexes and autonomic dysfunction [5]. The neurotoxicity of vincristine is dose-dependent and early intervention can sometimes mitigate severe outcomes [6].

d) Proteasome Inhibitors

Proteasome inhibitors like bortezomib are used in the treatment of multiple myeloma and mantle cell lymphoma. Bortezomib-induced peripheral neuropathy (BIPN) is a significant clinical problem, often presenting as painful sensory neuropathy. The pathogenesis of BIPN involves mitochondrial dysfunction, endoplasmic reticulum stress and inflammatory responses leading to dorsal root ganglion neuron damage [7].

e) Immunomodulatory Drugs

Thalidomide and its analogs, lenalidomide and pomalidomide are immunomodulatory drugs that have shown efficacy in the treatment of multiple myeloma. However, they are also associated with peripheral neuropathy which can be dose-limiting. The mechanisms of thalidomide-induced neurotoxicity are not well understood but may involve anti-angiogenic effects and direct neuronal damage [8].

3.2 Clinical Manifestations of Neurotoxicity

The clinical manifestations of chemotherapy-induced neurotoxicity vary depending on the agent, dose and duration of treatment. Neurotoxicity can affect both the CNS and PNS leading to a wide range of symptoms.

a) Peripheral Neuropathy

Peripheral neuropathy is the most common neurotoxic side effect of chemotherapy. It typically presents as a sensory neuropathy with symptoms such as numbness, tingling, burning pain and loss of proprioception. Motor involvement can lead to muscle weakness and atrophy while autonomic neuropathy may cause orthostatic hypotension, constipation and urinary retention. Table 1 summarizes the neurotoxic effects of various chemotherapeutic agents on the PNS.

Table 1: Neurotoxic effects of various chemotherapeutic agents on the Peripheral Nervous System

Chemotherapeutic Agent	Type of Neuropathy	Symptoms	Onset
Cisplatin	Sensory, motor	Numbness, tingling, muscle weakness	Cumulative dose
Paclitaxel	Sensory	Burning pain, "stocking-glove" distribution	Cumulative dose
Vincristine	Sensory, Motor, Autonomic	Muscle weakness, constipation, urinary retention	Early onset
Bortezomib	Sensory	Painful neuropathy, loss of reflexes	Cumulative dose
Thalidomide	Sensory	Numbness, tingling, ataxia	Cumulative dose

b) Central Nervous System Toxicity

CNS toxicity is less common than peripheral neuropathy but can have significant consequences. Chemotherapy-induced CNS toxicity can present as cognitive dysfunction, mood changes, seizures, and encephalopathy. For example, high-dose methotrexate can cause acute toxic encephalopathy presenting with confusion, seizures and focal neurological deficits [9]. Table 2 provides an overview of the neurotoxic effects on the CNS by different chemotherapeutic agents.

Table 2: Neurotoxic effects on the CNS by different chemotherapeutic agents

Chemotherapeutic Agent	Type of CNS Toxicity	Symptoms	Onset
Methotrexate	Encephalopathy	Confusion, seizures, focal deficits	Acute or delayed
Ifosfamide	Encephalopathy	Confusion, somnolence, hallucinations	Acute
Cytarabine	Cerebellar toxicity	Ataxia, dysarthria, nystagmus	Acute or delayed
Fludarabine	Cognitive dysfunction	Memory loss, confusion, mood changes	Delayed
Intrathecal chemotherapy	Aseptic meningitis	Headache, neck stiffness, fever	Acute

3.3 Mechanisms of Chemotherapy-Induced Neurotoxicity

The exact mechanisms of chemotherapy-induced neurotoxicity are complex and multifactorial, involving direct and indirect pathways of neuronal injury. Understanding these mechanisms is crucial for developing targeted strategies to prevent and manage neurotoxic side effects.

a) Oxidative Stress and Mitochondrial Dysfunction
Many neurotoxic chemotherapeutic agents, including cisplatin and paclitaxel, induce oxidative stress, leading to the generation of reactive oxygen species (ROS). Excessive ROS can damage mitochondrial DNA, proteins and lipids, resulting in mitochondrial dysfunction and subsequent neuronal apoptosis [10].

b) Microtubule Disruption
Taxanes and vinca alkaloids disrupt microtubule dynamics, which are essential for axonal transport and neuronal function. This disruption can lead to axonal degeneration and peripheral neuropathy. The impairment of microtubule-based transport also affects the distribution of organelles and proteins, contributing to neuronal dysfunction [11].

c) DNA Damage and Apoptosis
Platinum-based compounds cause DNA crosslinking and adduct formation leading to DNA damage and apoptosis in neurons. Neurons are particularly vulnerable to DNA damage due to their limited capacity for DNA repair [12].

d) Inflammation and Immune-Mediated Mechanisms
Inflammatory responses and immune-mediated mechanisms also play a role in chemotherapy-induced neurotoxicity. For example, bortezomib-induced neurotoxicity involves activation of pro-inflammatory cytokines and immune cells, which can exacerbate neuronal damage [13].

3.4 Prevention and Management of Neurotoxicity

Effective management of chemotherapy-induced neurotoxicity involves both preventive and therapeutic strategies. Early identification of at-risk patients and dose adjustments are critical in preventing severe neurotoxicity. Several agents have been investigated for their neuroprotective effects, though results have been mixed.

a) Dose Modification and Drug Substitution
Dose modification is often necessary in patients experiencing significant neurotoxicity. Reducing the dose or extending the interval between doses can help minimize neurotoxic effects while still maintaining the therapeutic efficacy of the chemotherapy regimen [14]. For example, in patients with severe cisplatin-induced neuropathy, substituting cisplatin with carboplatin which has a lower neurotoxic profile can be considered [15]. Similarly weekly administration of paclitaxel instead of the standard every-three-week schedule has been shown to reduce the incidence and severity of peripheral neuropathy [16].

b) Neuroprotective Agents
Several neuroprotective agents have been studied for their potential to prevent or reduce chemotherapy-induced neurotoxicity. However, the results have been mixed and no agent has been universally accepted for clinical use.

- Calcium and Magnesium Infusions:
  Infusions of calcium and magnesium have been investigated as a preventive measure for oxaliplatin-induced neurotoxicity. Some studies have shown a reduction in acute neurotoxicity symptoms without compromising the efficacy of oxaliplatin [17]. However other studies have raised concerns about the potential reduction in the chemotherapeutic efficacy of oxaliplatin [18].
- Glutathione:
  Glutathione, an antioxidant, has been studied for its protective effects against cisplatin-induced neurotoxicity. Clinical trials have demonstrated that glutathione administration can reduce the incidence of neuropathy in patients undergoing cisplatin therapy without affecting the anticancer efficacy [19].
- Duloxetine:
  Duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI) has shown promise in managing chemotherapy-induced neuropathic pain. A randomized controlled trial demonstrated that duloxetine significantly reduced pain in patients with chemotherapy-induced peripheral neuropathy (CIPN)[20].
- Acetyl-L-Carnitine:
  Acetyl-L-carnitine, a mitochondrial cofactor, has been studied for its potential to protect against paclitaxel-induced neuropathy. While some studies have shown both protective effect and no benefit which indicating the need for further research [21].

c) Physical and Occupational Therapy
Rehabilitation through physical and occupational therapy is an essential component of managing chemotherapy-induced neurotoxicity. Patients with peripheral neuropathy can benefit from exercises that improve balance, strength and coordination. Additionally occupational therapy can help patients adapt to sensory deficits improving their ability to perform daily activities [22].

d) Patient Education and Monitoring
Educating patients about the potential neurotoxic effects of chemotherapy and the importance of reporting symptoms early is crucial for timely intervention. Regular monitoring of neurological function during chemotherapy can help detect early signs of neurotoxicity allowing for dose adjustments or the introduction of protective strategies before severe damage occurs [23].

4. Discussion

Chemotherapy-induced neurotoxicity presents a significant challenge in cancer treatment, affecting a substantial proportion of patients undergoing chemotherapy. The mechanisms underlying neurotoxicity are complex involving oxidative stress, mitochondrial dysfunction, DNA damage, microtubule disruption and inflammatory processes. Despite advances in understanding these mechanisms, effective strategies for prevention and management remain limited.

This review highlights the importance of individualized treatment approaches, including dose modification, drug substitution and the use of neuroprotective agents in mitigating the impact of neurotoxicity. While neuroprotective agents such as calcium and magnesium infusions, glutathione

and duloxetine have shown promise in clinical trials, further research is needed to establish their efficacy and safety in larger and more diverse patient populations.

Future research should focus on identifying biomarkers that can predict susceptibility to neurotoxicity enabling personalized treatment strategies. Additionally, there is a need for the development of new therapeutic agents that offer potent anticancer effects with minimal neurotoxic side effects. The integration of novel drug delivery systems such as nanoparticle-based therapies could also reduce the off-target effects of chemotherapy on the nervous system [24].

Furthermore, the role of rehabilitation and supportive care in the management of neurotoxicity should not be overlooked. Physical and occupational therapy along with patient education are vital components of a comprehensive care plan aimed at maintaining the quality of life for patients experiencing neurotoxic side effects.

5. Conclusion

Neurotoxicity remains a major dose-limiting factor in cancer chemotherapy significantly impacting patient quality of life and treatment outcomes. Understanding the mechanisms of neurotoxicity and implementing effective prevention and management strategies are critical for optimizing cancer treatment. Ongoing research into neuroprotective agents, rehabilitation approaches and novel therapeutic strategies holds promise for reducing the burden of neurotoxicity in cancer patients. Healthcare providers should remain vigilant in monitoring for neurotoxic symptoms and proactively manage them to ensure that patients can continue to receive the most effective chemotherapy regimens without unnecessary interruptions or dose reductions. Collaborative efforts between oncologists, neurologists and rehabilitation specialists are essential to provide holistic care for patients experiencing chemotherapy-induced neurotoxicity.

This study is significant as it provides a comprehensive review of the neurotoxic effects of chemotherapy, which is critical for improving patient outcomes and guiding future research in developing safer cancer treatment protocols.

References

[1] Ewertz M, Jensen AB. Late effects of breast cancer treatment and potentials for rehabilitation. Acta Oncol. 2011;50(2):187-93.
[2] Podratz JL, Knight AM, Ta LE, Staff NP, Gass JM, Genelin K, et al. Cisplatin induced mitochondrial DNA damage in dorsal root ganglion neurons. Neurobiol Dis. 2011;41(3):661-8.
[3] Argyriou AA, Polychronopoulos P, Iconomou G, Chroni E, Kalofonos HP. A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev. 2008;34(4):368-77.
[4] Park SB, Goldstein D, Lin CS, Krishnan AV, Friedlander M, Cassidy J, et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin. 2013;63(6):419-37.
[5] Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. *Curr Opin Neurol*. 2015;28(5):500-7.
[6] Gourie-Devi M, Venkatasubramanian R, Puri V, Arunodaya GR. Neurotoxic complications of cancer chemotherapy. J Assoc Physicians India. 1991;39(9):689-91.
[7] Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of multiple myeloma with bortezomib. J Clin Oncol. 2006;24(19):3113-20.
[8] Canta A, Chiorazzi A, Carozzi VA, Meregalli C, Oggioni N, Sala B, et al. Thalidomide and its analogs in the treatment of human cancer: focus on peripheral neuropathy. Expert Opin Drug Metab Toxicol. 2009;5(11):1463-71.
[9] Fornaciari G, Di Guardo R, Malatesta M, Marongiu F, Ceccarelli D, Ferrari S, et al. Histopathology and immunohistochemistry of methotrexate-induced leukoencephalopathy. Int J Exp Pathol. 2002;83(1):65-9.
[10] Peters CM, Jimenez-Andrade JM, Jonas BM, Sevcik MA, Koewler NJ, Ghilardi JR, et al. Intravenous paclitaxel administration in the rat induces a peripheral neuropathy characterized by macrophage infiltration and injury to sensory neurons and their supporting cells. Exp Neurol. 2007;203(1):42-54.
[11] Boyette-Davis JA, Cata JP, Driver LC, Novy DM, Bruel BM, Mooring DL, et al. Persistent chemoneuropathy in patients receiving the plant alkaloids paclitaxel and vincristine. Cancer Chemother Pharmacol. 2013;71(3):619-26.
[12] McDonald ES, Randon KR, Knight A, Lyon AR. Cisplatin-induced neurotoxicity: Mechanisms and prospective studies in children. Pediatr Blood Cancer. 2015;62(3):395-8.
[13] Landowski TH, Megli CJ, Nullmeyer KD, Lynch RM, Dorr RT. Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. Cancer Res. 2005;65(9):3828-36.
[14] Kerckhove N, Collin A, Fouré A, Misery L, Leclair-Visonneau L, Authier N, et al. Long-term effects of chemotherapy on peripheral nervous system, cognitive functions and quality of life: A follow-up study on cisplatin-treated testicular cancer survivors. Support Care Cancer. 2021;29(1):197-208.
[15] Pignata S, De Placido S, Biamonte R, Scambia G, Di Vagno G, Colucci G, et al. Residual neurotoxicity in ovarian cancer patients treated with cisplatin, paclitaxel and carboplatin. Eur J Cancer. 2001;37(3):364-7.
[16] Von Hehn C, Baron R, Woolf CJ. Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. Neuron. 2012;73(4):638-52.
[17] Grothey A, Nikcevich DA, Sloan JA, Kugler JW, Silberstein PT, Dentchev T, et al. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol. 2011;29(4):421-7.
[18] Gamelin L, Capitain O, Morel A, Dumont A, Traore S, Brown C, et al. Predictive factors of oxaliplatin

neurotoxicity: the involvement of the oxalate outcome pathway. Clin Cancer Res. 2007;13(21):6359-68.
[19] Cascinu S, Catalano V, Cordella L, Labianca R, Giordani P, Baldelli AM, et al. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. J Clin Oncol. 2002;20(1):3470-5.
[20] Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309(13):1359-67.
[21] Bianchi G, Vitali G, Caraceni A, Ravaglia S, Capri G, Cundari S, et al. Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-l-carnitine. Eur J Cancer. 2005;41(12):1746-50.
[22] Hanewinckel R, Drenthen J, Verlinden VJ, et al. Peripheral neuropathy is associated with gait disturbances and the risk of falls in older adults. J Am Geriatr Soc. 2016;64(1):1767-73.
[23] Kaley TJ, DeAngelis LM. Therapy of chemotherapy-induced peripheral neuropathy. Br J Haematol. 2009;145(1):3-14.
[24] Zhao Y, Sultan D, Zhang Y, Zhou M, Hu W, Li W, et al. Nano-chemotherapy: Emerging approaches for enhancing the efficacy and safety of cancer chemotherapy. Curr Med Chem. 2021;28(27):5459-84.